# Y K Onno Teng

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/y-k-onno-teng/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,605 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 42 |
| i10-index | 79 |
| Last Known Institution | Leiden University Medical Center |
| OpenAlex ID | https://openalex.org/A5081323703 |
| ORCID iD | 0000-0001-9920-2195 |
| Works | 193 |

## Researcher papers

- [Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis](https://scholariq.org/papers/two-year-randomized-controlled-trial-of-belimumab-in-lupus-nephritis/)
- [EULAR recommendations for the management of systemic lupus erythematosus: 2023 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-systemic-lupus-erythematosus-2023/)
- [2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis](https://scholariq.org/papers/2019-update-of-the-joint-european-league-against-rheumatism-and-european-renal/)
- [EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-anca-associated-vasculitis-2022/)
- [Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-voclosporin-versus-placebo-for-lupus-nephritis-aurora-1-a/)
- [2021 DORIS definition of remission in SLE: final recommendations from an international task force](https://scholariq.org/papers/2021-doris-definition-of-remission-in-sle-final-recommendations-from-an/)
- [A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis](https://scholariq.org/papers/a-secondary-analysis-of-the-belimumab-international-study-in-lupus-nephritis/)
- [Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment](https://scholariq.org/papers/immunohistochemical-analysis-as-a-means-to-predict-responsiveness-to-rituximab/)
- [Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis](https://scholariq.org/papers/clinical-and-histopathologic-characteristics-associated-with-renal-outcomes-in/)
- [The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus](https://scholariq.org/papers/the-net-effect-of-combining-rituximab-with-belimumab-in-severe-systemic-lupus/)
- [TAC-TIC use of tacrolimus-based regimens in lupus nephritis](https://scholariq.org/papers/tac-tic-use-of-tacrolimus-based-regimens-in-lupus-nephritis/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Otitis Media and Relapsing Polychondritis](https://scholariq.org/topics/otitis-media-and-relapsing-polychondritis/)

## Researcher university

- [Leiden University Medical Center](https://scholariq.org/institutions/leiden-university-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.